• Je něco špatně v tomto záznamu ?

Quantification of extracellular DNA using hypermethylated RASSF1A, SRY, and GLO sequences--evaluation of diagnostic possibilities for predicting placental insufficiency

I. Hromadnikova, L. Zejskova, K. Kotlabova, T. Jancuskova, J. Doucha, K. Dlouha, L. Krofta, JE. Jirasek, R. Vlk,

. 2010 ; 29 (6) : 295-301.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12025867

This study evaluated quantification of fetal extracellular DNA in maternal plasma for differentiation between cases at risk of onset of placental-insufficiency-related complications and normal pregnancies. Using real-time polymerase chain reaction, fetal (sex-determining region Y [SRY] and hypermethylated RASSF1A sequence) and total (beta-globin [GLO] gene) extracellular DNA was examined in 70 normal pregnancies, 18 at risk of placental-insufficiency-related pregnancy complications, 24 preeclampsia with or without (w or w/o) intrauterine growth retardation (IUGR) (median 34.0 week), and 11 IUGR (median 28.5 week). IUGR was diagnosed when estimated fetal weight was below the 10th percentile for evaluated gestational age. Although increased levels of extracellular DNA were detected in pregnancies with preeclampsia w or w/o IUGR relative to controls (RASSF1A, p < 0.001; SRY, p = 0.009; GLO, p < 0.001), quantities of fetal extracellular DNA in IUGR were not statistically significant (RASSF1A, p = 0.21; SRY, p = 0.2). RASSF1A, SRY, and GLO achieved 93.1%, 93.6%, and 92.1% accuracy for differentiation between normal pregnancy and preeclampsia w or w/o IUGR. Lower sensitivity was observed for pregnancies with onset of IUGR (RASSF1A, 60.0%; SRY, 80.0%; GLO, 72.7%), but did not influence final accuracy (RASSF1A, 91.6%; SRY, 92.5%; GLO, 89.5%). Among 18 patients at risk, 8 pregnancies involving 3 female and 5 male fetuses developed preeclampsia (n = 4), IUGR (n = 3), and chronic placentopathy causing hypoxia (n = 1). Elevation of extracellular DNA was demonstrated in 3/5 (SRY), 1/8 (hypermethylated RASSF1A), and 4/8 (GLO) patients at the earliest 26 weeks and at the latest 2 weeks before the onset of symptoms. These data indicate that fetal and total extracellular DNA concentrations can be significantly elevated in plasma of patients who later developed placental-insufficiency-related pregnancy complications. However, this is strongly individualized, and not a rule for all cases, and probably depends on the actual occurrence of excessive placental trophoblast apoptosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025867
003      
CZ-PrNML
005      
20121207094552.0
007      
ta
008      
120817s2010 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1089/dna.2009.0971 $2 doi
035    __
$a (PubMed)20235876
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hromadnikova, Ilona $u Department of Molecular Biology and Cell Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. ilona.hromadnikova@lf3.cuni.cz
245    10
$a Quantification of extracellular DNA using hypermethylated RASSF1A, SRY, and GLO sequences--evaluation of diagnostic possibilities for predicting placental insufficiency / $c I. Hromadnikova, L. Zejskova, K. Kotlabova, T. Jancuskova, J. Doucha, K. Dlouha, L. Krofta, JE. Jirasek, R. Vlk,
520    9_
$a This study evaluated quantification of fetal extracellular DNA in maternal plasma for differentiation between cases at risk of onset of placental-insufficiency-related complications and normal pregnancies. Using real-time polymerase chain reaction, fetal (sex-determining region Y [SRY] and hypermethylated RASSF1A sequence) and total (beta-globin [GLO] gene) extracellular DNA was examined in 70 normal pregnancies, 18 at risk of placental-insufficiency-related pregnancy complications, 24 preeclampsia with or without (w or w/o) intrauterine growth retardation (IUGR) (median 34.0 week), and 11 IUGR (median 28.5 week). IUGR was diagnosed when estimated fetal weight was below the 10th percentile for evaluated gestational age. Although increased levels of extracellular DNA were detected in pregnancies with preeclampsia w or w/o IUGR relative to controls (RASSF1A, p < 0.001; SRY, p = 0.009; GLO, p < 0.001), quantities of fetal extracellular DNA in IUGR were not statistically significant (RASSF1A, p = 0.21; SRY, p = 0.2). RASSF1A, SRY, and GLO achieved 93.1%, 93.6%, and 92.1% accuracy for differentiation between normal pregnancy and preeclampsia w or w/o IUGR. Lower sensitivity was observed for pregnancies with onset of IUGR (RASSF1A, 60.0%; SRY, 80.0%; GLO, 72.7%), but did not influence final accuracy (RASSF1A, 91.6%; SRY, 92.5%; GLO, 89.5%). Among 18 patients at risk, 8 pregnancies involving 3 female and 5 male fetuses developed preeclampsia (n = 4), IUGR (n = 3), and chronic placentopathy causing hypoxia (n = 1). Elevation of extracellular DNA was demonstrated in 3/5 (SRY), 1/8 (hypermethylated RASSF1A), and 4/8 (GLO) patients at the earliest 26 weeks and at the latest 2 weeks before the onset of symptoms. These data indicate that fetal and total extracellular DNA concentrations can be significantly elevated in plasma of patients who later developed placental-insufficiency-related pregnancy complications. However, this is strongly individualized, and not a rule for all cases, and probably depends on the actual occurrence of excessive placental trophoblast apoptosis.
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a DNA $x genetika $7 D004247
650    _2
$a metylace DNA $7 D019175
650    _2
$a extracelulární prostor $x genetika $7 D005110
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a plod $x cytologie $7 D005333
650    _2
$a genetické markery $x genetika $7 D005819
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a matky $7 D009035
650    _2
$a placentární insuficience $x krev $x diagnóza $x genetika $7 D010927
650    _2
$a těhotenství $7 D011247
650    _2
$a riziko $7 D012306
650    _2
$a protein oblasti určující pohlaví na chromozomu Y $x krev $x genetika $7 D051876
650    _2
$a časové faktory $7 D013997
650    _2
$a nádorové supresorové proteiny $x krev $x genetika $7 D025521
650    _2
$a beta-globiny $x genetika $x metabolismus $7 D055544
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zejskova, Lenka
700    1_
$a Kotlabova, Katerina
700    1_
$a Jancuskova, Tereza
700    1_
$a Doucha, Jindrich
700    1_
$a Dlouha, Klara
700    1_
$a Krofta, Ladislav
700    1_
$a Jirasek, Jan E
700    1_
$a Vlk, Radovan
773    0_
$w MED00007256 $t DNA and cell biology $x 1557-7430 $g Roč. 29, č. 6 (2010), s. 295-301
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20235876 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121207094626 $b ABA008
999    __
$a ok $b bmc $g 947909 $s 783213
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 29 $c 6 $d 295-301 $i 1557-7430 $m DNA and cell biology $n DNA Cell Biol $x MED00007256
LZP    __
$a Pubmed-20120817/10/03

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...